A5090830952- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Pregnancy and preeclampsia studies
- Maternal and Neonatal Healthcare
- Global Maternal and Child Health
- Nonmelanoma Skin Cancer Studies
- Sarcoma Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Renal cell carcinoma treatment
- Cutaneous Melanoma Detection and Management
- Gastric Cancer Management and Outcomes
- Pancreatic and Hepatic Oncology Research
- Cancer and Skin Lesions
- Melanoma and MAPK Pathways
- Hepatocellular Carcinoma Treatment and Prognosis
- Hedgehog Signaling Pathway Studies
- Gestational Diabetes Research and Management
- Polyomavirus and related diseases
- Cancer Treatment and Pharmacology
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Hemoglobinopathies and Related Disorders
- Thyroid Cancer Diagnosis and Treatment
- Renal and related cancers
- Chemotherapy-related skin toxicity
- DNA Repair Mechanisms
Hospital Sírio-Libanês
2021-2025
Hospital São Paulo
2022
Centro Universitário Lusíada
2016-2017
University of Lusaka
2017
Abstract Background Immune checkpoint inhibitors (ICIs) have significantly advanced cancer therapy, yet their efficacy in tumors with low tumor mutational burden (TMB) remains suboptimal. In this study, we aimed to elucidate the impact of somatic mutations on overall survival (OS) TMB-low patients treated ICIs and explore potential for personalized treatment selection through machine learning. Methods We conducted a comprehensive analysis 1172 (TMB < 10 per megabase) receiving ICIs,...
Purpose: Solid tumors harboring tumor mutational burden (TMB) ≥10 mutations per megabase (mut/Mb) received agnostic approval for pembrolizumab. This work aims to analyze the somatic profile’s influence on outcomes of patients with TMB-high treated immune checkpoint inhibitors (ICIs). Methods: post-hoc analysis evaluated clinical and molecular features solid ICIs that could be either monoclonal antibody directed against programmed cell death protein-1 or ligand 1 (anti-PD-1/anti-PD-L1),...
ABSTRACT Purpose Solid tumors harboring tumor mutational burden (TMB) ≥ 10 mutations per megabase (mut/Mb) received agnostic approval for pembrolizumab. However, TMB cut-off alone is not a predictor of overall survival (OS). This work aims to analyze the somatic profile’s influence in outcomes patients with TMB-high treated immune checkpoint inhibitors (ICIs). Methods post-hoc analysis evaluated clinical and molecular features 1,661 solid ICIs. We performed OS thresholds 10, 20, < mut/Mb....
Recognition of the molecular basis gastrointestinal stromal tumors has paved way for significant breakthroughs in diagnosis and treatment this disease as well positioned a framework concept precision oncology solid tumors. The incorporation novel targeted agents molecularly defined subgroups led to improvements outcomes; however, characterization heterogeneous KIT or PDGFRA mutations emergence resistance mechanisms highlight need broader use comprehensive profiling emphasize importance...
Werner's syndrome is caused by the inactivation of both WRN alleles and characterized premature aging increased risk neoplasms, especially those mesenchymal origins, such as sarcomas. Given characteristic genomic instability, patients with this are more susceptible to develop toxicities when exposed cytotoxic agents, alkylators anthracyclines. The impact monoallelic mutation on treatment-associated poorly understood. Here, we report a patient locally advanced dedifferentiated liposarcoma...
Hepatoid adenocarcinoma of the stomach is an uncommon subtype gastric cancer remarkably similar to hepatocellular carcinoma in histopathological analysis. It also commonly associated with high serum alfa-fetoprotein and a poorer prognosis, despite emergence new therapeutic options. In recent years, next generation sequencing (NGS) technology has made it possible identify describe genes molecular alterations common thereby contributing advancement targeted therapies. A 62-year-old patient, no...
2632 Background: High-TMB was recently approved as an agnostic biomarker for pembrolizumab in advanced cancers. Still, several patients with high-TMB do not respond to ICI, while some low-TMB benefit from immunotherapy. Methods: We collected genomic (MSK-IMPACTassay) and survival data 1,661 assessed OS (Kaplan-Meier method) according the mutational status. To better qualify TMB ≥ 10 mut/Mb (TMB-H) (N = 488, 29%) < (TMB-L) 1,173, 71%) ICI treatment, we analyzed single gene alterations...